Loading
Respiratory Diseases / Mrna Therapeutics / Mrna Delivery · Journal article
International Journal of Pharmaceutics: X · August 16, 2026
A consensus or society position rather than new primary data.
This is a comprehensive narrative review of mRNA therapeutics for respiratory disease, tracing evolution of lipid nanoparticle (LNP) design across three generations and examining delivery to diverse lung cell types. While the review documents proof-of-concept (e.g., MRT5005 Phase I/II in cystic fibrosis) and identifies readily targetable populations (airway epithelia, alveolar type II cells, macrophages), it emphasizes substantial translational gaps, including inadequate long-term safety data for repeated dosing, poor predictive value of healthy rodent models, and formidable barriers in lung cancer where tumor stromal and immunosuppressive microenvironments impair LNP delivery.
Narrative review article. Review covers therapeutic approaches for pulmonary disorders (cystic fibrosis, idiopathic pulmonary fibrosis, lung cancer) in preclinical models and early clinical trials; MRT5005 data from Phase I/II in cystic fibrosis patients..
Mucus-penetrating formulations achieved approximately 30% delivery efficiency to ATII cells within fibrotic mouse lungs, sufficient for functional restoration in bleomycin-induced pulmonary fibrosis model. Nebulized CFTR-encoding mRNA (MRT5005) produced dose-dependent improvements in chloride transport in Phase I/II clinical trials. Second-generation lung-homing LNPs achieved ∼95% lung selectivity via SORT technology.
Long-term safety data for repeated mRNA-LNP dosing not detailed; review identifies this as a gap but does not provide incidence figures. Source does not report efficacy or safety outcomes from MRT5005 Phase I/II trials; only states 'dose-dependent improvements' without effect size, p-value, or adverse event rates.
Clinicians should recognize that while mRNA-LNP delivery to airway and alveolar epithelium is established (with MRT5005 providing early proof-of-concept in CF), significant preclinical and regulatory hurdles remain before broader clinical deployment, particularly for repeated dosing regimens, lung cancer indications, and rare cell types. The field requires validation in disease-relevant models rather than reliance on healthy rodent systems.
This is a systematic review article synthesizing mechanisms, delivery methods, challenges, and safety considerations for mRNA-LNP therapeutics in pulmonary disorders, providing expert assessment of the field rather than reporting original trial data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that while mRNA-LNP delivery to airway and alveolar epithelium is established (with MRT5005 providing early proof-of-concept in CF), significant preclinical and regulatory hurdles remain before broader clinical deployment, particularly for repeated dosing regimens, lung cancer indications, and rare cell types. The field requires validation in disease-relevant models rather than reliance on healthy rodent systems.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The success of mRNA vaccines has established lipid nanoparticles (LNPs) as a clinically validated delivery platform, yet their application to pulmonary therapeutics presents formidable challenges. This review systematically summarizes the mechanisms, delivery methods, key challenges, safety considerations, and translational gaps associated with mRNA-LNP therapeutics for pulmonary disorders. It surveys LNP-mediated delivery to pulmonary cell populations, distinguishing readily accessible targets (such as alveolar type II cells, bronchial epithelia, and macrophages) from refractory cell types (including T cells and rare fibroblast subsets). The evolution of LNPs is traced through three generations: from initial hepatic-optimized carriers, to lung-tropic selective organ targeting (SORT) formulations, and onward to contemporary precision-engineered aerosol systems. These advances have enabled diverse mRNA-based therapeutic modalities, encompassing protein replacement, gene editing, cell reprogramming, and cancer immunotherapy, each of which is examined with emphasis on their distinct mechanisms of action and safety profiles. Lung cancer represents a particularly intractable therapeutic challenge. Stromal barriers and tumor-associated macrophages render most lung-selective LNPs ineffective in orthotopic models, necessitating development strategies decoupled from those for non-malignant indications. Significant translational gaps persist, including a limited understanding of inhaled delivery barriers, insufficient long-term safety data for repeated dosing regimens, and the poor predictive value of healthy rodent models. While AI-guided lipid discovery, biodegradable formulations, and active targeting strategies offer considerable promise, clinical success will demand rigorous validation in disease-relevant preclinical models.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.